Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics, SelectHealth Sign Coverage Agreement for Thyroid Cancer Tests

NEW YORK— Interpace Diagnostics announced today that it has signed an agreement with SelectHealth/Intermountain Healthcare to offer its thyroid cancer detection assays to SelectHealth's 850,000 members in Utah and Idaho. 

As part of the agreement, physicians across SelectHealth's entire network can now use Interpace's ThyGeNext and ThyraMir assays to test questionable thyroid nodules for potential evidence of thyroid cancer.

In addition, Interpace said it will act as an in-network laboratory for these services to SelectHealth's members. 

"This continues the trend we have seen among other healthcare plans, both national and regional, to make our unique ThyGeNext/ThyraMir combination tests available to their members," Interpace CEO Jack Stover said in a statement.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.